Latest news with #minimallyinvasive
Associated Press
2 days ago
- Business
- Associated Press
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Olympus Co-founds Swan EndoSurgical With Revival Healthcare Capital TOKYO - July 28, 2025 ( NEWMEDIAWIRE ) - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, today announced the conclusion of an agreement with Revival Healthcare Capital (Revival) to drive advancements in endoluminal robotics. Olympus and Revival will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed to revolutionize gastrointestinal (GI) patient care in the future. Endoluminal robotics aims to empower more physicians to safely perform innovative techniques, enhancing patient access to treatment options that support safety and improved recovery times. This groundbreaking advancement has the potential to create new and significantly enhanced minimally invasive treatment options for major unmet medical needs by boosting precision and efficiency in procedures addressing ergonomic strain for healthcare professionals. Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus, commented, 'This partnership marks a significant milestone in our strategic initiative to advance endoluminal robotics. We are excited to enter this collaboration that we expect to play a pivotal role in reshaping the GI market by expanding procedural capabilities for physicians. This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population.' For decades, endoscopy - placing a flexible camera into an existing body orifice - has yielded early and accurate diagnoses of conditions such as GI tract cancer. In recent years, specialists, primarily gastroenterologists, have begun performing endoscopic therapeutic procedures, such as cancer resection, by inserting instruments through the endoscope. However, manual endoscopes and their instruments have limitations that make many advanced procedures within the lumen of the GI tract challenging and not widely available globally. The development of an endoluminal robot, with its ability to easily maneuver within the GI tract and deploy flexible arms, provides the opportunity for more patients to benefit from safe and effective procedures, potentially avoiding invasive surgery. This innovation allows for the early, safe, and effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. Furthermore, the technology has the potential for application in numerous other disease areas. Headquartered in the United States, Swan EndoSurgical has assembled a leadership team of highly experienced industry professionals who will drive technical, clinical, and commercial development of the robotic platform. About Swan EndoSurgical Swan EndoSurgical, Inc. is an innovative start-up co-founded by Revival Healthcare Capital and Olympus that is focused on the development of endoluminal surgical robotics with the aim to create effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. For additional information, visit the Company's website at or contact [email protected]. About Revival Healthcare Capital Revival Healthcare Capital is an investment firm focused on the MedTech sector. Revival specializes in transformative external innovation partnerships and other opportunities where its team of experienced operators and investors believes it can provide leadership, resources, and deep sector insights - beyond its capital - to further support companies' growth strategies. For additional information, visit Revival's website at or contact [email protected] . About Olympus At Olympus, we are committed to Our Purpose of making people's lives healthier, safer, and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis, and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit and follow our global X account: @Olympus_Corp. Media contact: Mail: [email protected] Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS]
Yahoo
7 days ago
- Business
- Yahoo
Intuitive Surgical reports upbeat quarterly earnings on strong demand for surgical robots
(Reuters) -Intuitive Surgical beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by growing demand for its surgical robots used in minimally invasive procedures. A steady rise in demand for elective surgeries has contributed to higher procedure volumes for medical device makers such as Intuitive Surgical in recent quarters. The company, known for its da Vinci robotic systems, has seen consistent growth as hospitals work through a backlog of deferred procedures and expand access to minimally invasive care. The medical device maker slightly raised its adjusted gross profit margin forecast for 2025 to between 66% and 67% of revenue, up from earlier estimates of 65% to 66.5%. The updated range includes an estimated impact from tariffs of 1% of revenue, plus or minus 20 basis points, Intuitive said, compared to previously estimated impact of 1.7% of revenue, plus or minus 30 basis points. Shares of the Sunnyvale, California-based company fell 1.5% in after-hours trading. More than 80% of the instruments and accessories for the company's da Vinci system are produced at Intuitive's facility in Mexico, while the company also operates in China and other international markets. Intuitive's worldwide da Vinci procedure volumes rose about 17% compared to the same quarter last year. The company expects global da Vinci-assisted procedures to increase by about 15.5% to 17% in 2025, up from its prior forecast of 15% to 17%. On an adjusted basis, the medical device maker earned $2.19 per share for the quarter ended June 30, beating analysts' estimates of $1.92 per share, according to LSEG data. The company reported revenue of $2.44 billion for the second quarter, compared to analysts' estimates of $2.35 billion. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
Intuitive Surgical reports upbeat quarterly earnings on strong demand for surgical robots
(Reuters) -Intuitive Surgical beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by growing demand for its surgical robots used in minimally invasive procedures. A steady rise in demand for elective surgeries has contributed to higher procedure volumes for medical device makers such as Intuitive Surgical in recent quarters. The company, known for its da Vinci robotic systems, has seen consistent growth as hospitals work through a backlog of deferred procedures and expand access to minimally invasive care. The medical device maker slightly raised its adjusted gross profit margin forecast for 2025 to between 66% and 67% of revenue, up from earlier estimates of 65% to 66.5%. The updated range includes an estimated impact from tariffs of 1% of revenue, plus or minus 20 basis points, Intuitive said, compared to previously estimated impact of 1.7% of revenue, plus or minus 30 basis points. Shares of the Sunnyvale, California-based company fell 1.5% in after-hours trading. More than 80% of the instruments and accessories for the company's da Vinci system are produced at Intuitive's facility in Mexico, while the company also operates in China and other international markets. Intuitive's worldwide da Vinci procedure volumes rose about 17% compared to the same quarter last year. The company expects global da Vinci-assisted procedures to increase by about 15.5% to 17% in 2025, up from its prior forecast of 15% to 17%. On an adjusted basis, the medical device maker earned $2.19 per share for the quarter ended June 30, beating analysts' estimates of $1.92 per share, according to LSEG data. The company reported revenue of $2.44 billion for the second quarter, compared to analysts' estimates of $2.35 billion. Sign in to access your portfolio
Reuters
7 days ago
- Business
- Reuters
Intuitive Surgical reports upbeat quarterly earnings on strong demand for surgical robots
July 22 (Reuters) - Intuitive Surgical (ISRG.O), opens new tab beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by growing demand for its surgical robots used in minimally invasive procedures. A steady rise in demand for elective surgeries has contributed to higher procedure volumes for medical device makers such as Intuitive Surgical in recent quarters. The company, known for its da Vinci robotic systems, has seen consistent growth as hospitals work through a backlog of deferred procedures and expand access to minimally invasive care. The medical device maker slightly raised its adjusted gross profit margin forecast for 2025 to between 66% and 67% of revenue, up from earlier estimates of 65% to 66.5%. The updated range includes an estimated impact from tariffs of 1% of revenue, plus or minus 20 basis points, Intuitive said, compared to previously estimated impact of 1.7% of revenue, plus or minus 30 basis points. Shares of the Sunnyvale, California-based company fell 1.5% in after-hours trading. More than 80% of the instruments and accessories for the company's da Vinci system are produced at Intuitive's facility in Mexico, while the company also operates in China and other international markets. Intuitive's worldwide da Vinci procedure volumes rose about 17% compared to the same quarter last year. The company expects global da Vinci-assisted procedures to increase by about 15.5% to 17% in 2025, up from its prior forecast of 15% to 17%. On an adjusted basis, the medical device maker earned $2.19 per share for the quarter ended June 30, beating analysts' estimates of $1.92 per share, according to LSEG data. The company reported revenue of $2.44 billion for the second quarter, compared to analysts' estimates of $2.35 billion.
Medscape
11-07-2025
- Health
- Medscape
Mini-Invasive Surgery Eases Hemorrhoid Pain Fast
At a recent session of the National Academy of Surgery, experts highlighted that minimally invasive techniques are playing an increasingly central role in proctologic surgery. Béatrice Vinson-Bonnet, MD, visceral and digestive surgeon at Poissy-Saint-Germain-en-Laye Community Hospital, noted that treatment for hemorrhoidal disease has advanced significantly, moving away from traditional hemorrhoidectomy toward less invasive, technology-driven procedures. 'Thanks to advances in technology, all surgical approaches now aim to be as minimally invasive as possible,' said Vinson-Bonnet. 'However, before considering surgery, we prioritize medical treatment for hemorrhoidal disease — addressing intestinal transit disorders, particularly constipation, and educating patients on proper bowel habits.' Surgery is considered only when these measures fail to provide relief. Until the 2000s, hemorrhoidectomy was the primary surgical treatment for hemorrhoidal disease. Since then, less painful alternatives have emerged, including nerve blocks and stapling all designed to avoid external incisions and reduce postoperative pain and recovery times. One such option is the pudendal nerve block, which involves anesthetizing the pudendal nerve using a long-acting agent. This provides 12-24 hours of postoperative pain relief following hemorrhoid surgery. However, stool passage over the surgical site can still cause significant discomfort between days 3 and 10, and complete healing may take 6 weeks, Vinson-Bonnet noted. In 1998, Antonio Longo, MD, colorectal surgeon from Italy, and director of the European Centre for Coloproctology and Pelvic Diseases in Vienna, Austria, introduced stapled hemorrhoidopexy. This surgical technique uses a circular stapler to remove a circumferential ring of rectal mucosa above the hemorrhoids, repositioning prolapsing internal hemorrhoids to their normal anatomical position. 'Although innovative, stapled hemorrhoidopexy has been linked to serious complications and is now often replaced by a simpler technique that uses an anoscope to locate and ligate small rectal arteries,' said Vinson-Bonnet. According to Vinson-Bonnet, these techniques are limited to internal hemorrhoids and are not appropriate for large external hemorrhoids and do not allow the removal of large external hemorrhoids, often caused by thrombosis, particularly after childbirth in women. Another drawback is recurrence, with symptoms returning to up to 20% of patients within 2 years. 'Thermofusion, which uses microwave energy to completely dry out internal bleeding, is an emerging technique. While still under evaluation, it is already being used in clinical practice,' she added. 'Other recent methods, such as radiofrequency — and, more rarely, laser — are also employed,' said Vinson-Bonnet. Professor Émilie Duchalais, MD, PhD, digestive surgeon at Nantes University Hospital in Nantes, France, presented recent developments in minimally invasive treatment for fecal incontinence. She leads clinical and translational studies on this condition at the Institute of Digestive System Diseases. 'Sacral neuromodulation and Botox are two techniques mainly reserved for patients with fecal incontinence,' Duchalais explained. These are considered second- or third-line treatment options and are used only when medical treatment or rehabilitation has failed. Sacral neuromodulation involves stimulating nerve roots near the sacrum, which engage in sphincter control and rectal sensitivity. 'Five to 10 years after implantation, long-term improvement is seen in 50%-70% of patients,' said Duchalais. A major advantage of this method is that it allows a trial phase. Electrodes are temporarily implanted at the targeted site, enabling patients to evaluate the effectiveness of the treatment over 2-3 weeks. 'If the patient experiences at least a 50% reduction in incontinence episodes during this period, the device is permanently implanted. The system, similar to a pacemaker but placed in the buttocks, typically remains in place for at least 5 years, depending on the battery life,' she said. 'Urologists commonly use Botox to treat overactive bladder. Botox works by blocking acetylcholine, preventing muscle contractions, and reducing urinary leakage. In the rectum, Botox has a similar effect — blocking muscle activity and nerve signals to improve control in patients with fecal incontinence,' Duchalais noted. Although effective, Botox provides only temporary relief. 'Its effects typically last 6-9 months. However, a recent study showed that after 5 years, patients required injections only once every 3 years on average,' she added. Another approach currently under investigation is fat injection. 'Researchers are studying autologous fat injection into the anal sphincter as a potential treatment for urge incontinence. The technique aims to restore sphincter tone by harnessing the regenerative potential of stem cells found in fat tissue.' A clinical trial led by Rennes University Hospital, Rennes, France, is evaluating this method, and the early findings are promising. However, this approach remains experimental,' said Duchalais.
